Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

AMERICAN DIVERSIFIED HOLDINGS CORPORATION ANNOUNCES THE APPOINTMENT OF ANDREW BIRNBAUM AS CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD, EFFECTIVE IMMEDIATELY

American Diversified Holdings Corp.

American Diversified Holdings Corporation (OTC: ADHC) announced today the appointment of Andrew Birnbaum as Chief Executive Officer and Chairman of the Board, effective immediately. Mr. Birnbaum brings decades of experience in running and operating companies; he has significant and successful both private and public company Chief Executive Officer experience. His leadership and effective implementation of growth and development plans will be of good use in the revitalization of the holding company. “I am very appreciative of the work that Ernest has done to this point, and I am happy to see him finally enjoy his retirement. I respect the shareholder base and will do my best to provide continued value and benefits to them.’ Stated Mr. Birnbaum, CEO And Chairman. Ernest Remo commented: “Based on Andrew’s well-rounded experience and integrity, I am very pleased with his appointment and am excited to see the new changes with the company and how they benefit our shareholders.” About ADHC: American Diversified Holdings Corporation, operates alliances with Green Global International Group (GGII), Hempaco (HPCO) and GGII Subsidiary Green Star Labs. In addition, two e-commerce sites focused on these emerging technologies: universalwellness.co (not.com) and RollsChoiceAdhesives.com. The business model includes selling products to consumers, driving traffic to partner sites, generating ad revenue and creating partnership opportunities for other wellness companies. www.adhcinvestor.com Contact Details: Andrew Birnbaum (714) 599-2126 Info@adhcinvestor.com www.adhcinvestor.com American Diversified Holdings Corporation TWITTER: @ADHCManagement. This Twitter page is the only official Twitter page for ADHC. SAFE HARBOR FORWARD-LOOKING STATEMENTS: This press release may contain forward-looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as “estimate,” “project,” “predict,” “will,” “would,” “should,” “could,” “may,” “might,” “anticipate,” “plan,” “intend,” “believe,” “expect,” “aim,” “goal,” “target,” “objective,” “likely” or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise. Contact Details Andrew Birnbaum +1 714-599-2126 Info@adhcinvestor.com Company Website https://www.adhcinvestor.com/

May 16, 2023 06:00 AM Eastern Daylight Time

Genflow Biosciences reaffirms commitment to new markets

Genflow Biosciences PLC

Dr. Eric Leire, CEO of Genflow Biosciences PLC, recently announced exciting developments in the company's fight against nonalcoholic steatohepatitis (NASH), a liver disease that affects millions of people worldwide. Significant progress has been made in its pre-clinical program, targeting fat deposition, fibrosis, and liver cancer associated with NASH. The company has strengthened its Scientific Advisory Board with the addition of Professor Dr Sven Franque, an expert in NASH and regulatory authorities. Furthermore, Genflow has promoted Tamara Joseph as chairperson, reflecting their commitment to diversity and expanding their presence in the US market. They have also applied to trade on the OTC QB market, and Dr. Leire plans to increase their presence in the US. These advancements highlight Genflow's dedication to addressing the unmet need in NASH treatment. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

May 16, 2023 03:00 AM Eastern Daylight Time

Video

Kite Hill PR Reaches 10-Year Milestone

Kite Hill PR

Kite Hill PR, the award-winning agile tech PR and B2B communications agency, celebrates 10 years of business and has been named a Top B2B PR Agency by PR Daily. The award honors agencies that deliver on their promises to clients and raise the bar on effective communications strategies and tactics. The agency credits its success to its award-winning culture of collaboration, which has prioritized and operationalized mentorship. To celebrate this notable business milestone, the agency is launching a “Modern Mentorship” campaign highlighting advice from top female leaders on innovation, agility and collaboration. Helmed by an all-female leadership team, the agency has worked with over 180 clients in the last decade, organized and managed 30+ industry events and won 18 awards for its culture, leadership and the results it drives for clients. The company’s notable organic growth was bolstered by the acquisition of Cutler PR in 2018. With a history of working with tech innovators, the agency’s practice areas currently include adtech, media, B2B tech, healthtech, fintech, climate tech, cybersecurity and mobility. Kite Hill PR’s founding team launched Communications Week® in 2014, a preeminent event created to inspire, inform and connect those in PR and communications, which was acquired by Ragan Communications in 2021. The company’s innovative approach to agile PR, the PR Sprint ® Workflow, was launched in 2018 and the company was awarded a US trademark for this unique approach to managing PR campaigns in 2021. “I attribute our continued success to our culture of innovation, collaboration and learning. Over the last decade, we have focused on supporting our team through robust learning and development resources to fuel growth and encourage innovative thinking,” said Tiffany Guarnaccia, CEO and Founder of Kite Hill PR. “Mentorship plays a huge role in my life and in our agency. In the spirit of collaboration, we’re marking our anniversary by celebrating modern mentorship.” The anniversary video series “Modern Mentorship” highlights perspectives from industry luminaries on mentorship and features reflections from the last decade along with actionable tips for professionals seeking career advice. Interviewees include Janet Balis, Partner, CMO Practice Leader - Business Transformation, EY; Shannan Herbert, EVP, Inclusive Credit; Tameka Kee, Deputy Managing Director, Coalition for Innovative Media Measurement; Bonnie Kintzer, President and CEO, TMB; Linda Ong, CEO and founder, CULTIQUE; Tiffany Ricks, CEO, HacWare; Diane Schwartz, CEO, Ragan Communications; Patrice Tanaka, founder, Joyful Planet; Tonia Wellons, President and CEO, Greater Washington Community Foundation and Lisa Marrocchino, CEO of Proteus Ocean Group. Videos will be released on the Kite Hill PR website, LinkedIn and YouTube today through July 2023. “As we continue to shape a best-in-class work from anywhere culture, we have operationalized our L&D program to make mentorship a part of our DNA. We cultivate peer-to-peer relationships based on various parameters, encourage reverse mentoring, and create opportunities for department levels to problem solve and learn from one another,” said Guarnaccia. “The campaign is a natural extension of Kite Hill PR’s ethos as we seek to strengthen the PR industry at large and empower the next generation of leaders.” To learn more about Kite Hill PR’s unique approach to mentorship and its Modern Mentorship campaign, visit https://www.kitehillpr.com/modern-mentorship Headquartered in New York City with team members in the UK and across North America, Kite Hill PR is a leading B2B communications and agile tech PR agency with practice areas in adtech, martech and creative agencies; B2B and enterprise tech; climate tech; cybersecurity; fintech; healthtech; media and entertainment and mobility. The company's winning approach combines thought leadership, strategy and media relations to drive clients' businesses forward. Kite Hill PR has been recognized as one of the "Top Tech Specialist PR Agencies in NYC,” “Most Powerful PR Firms,” and a “Top 50 PR Firm in America” by the Observer, a “Best Place to Work” by PR News and one of "America's Best PR Agencies" by Forbes Contact Details Kite Hill PR Kerriann Becker kerriann@kitehillpr.com

May 15, 2023 10:31 AM Eastern Daylight Time

SS Innovations International, Inc. (f/k/a Avra Medical Robotics, Inc.) Commences Trading under “SSII” Ticker Symbol and Provides Corporate Update

SS Innovations International Inc

SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population, today released a corporate update. Recent Highlights Effective with the open of trading on Monday, May 15, 2023, SSII common stock, whose ticker symbol was AVMR, then AVMRD for 20 trading days following its merger on April 14, 2023, will begin trading under the ticker symbol “SSII”, as confirmed by FINRA on May 12, 2023. On April 19, 2023, the Company, then known as AVRA Medical Robotics, Inc., completed its merger, changed its corporate name to SS Innovations International, Inc. (“SSII”), and implemented a one-for-ten reverse stock split. SS Innovations is led by a topflight medical and engineering team including: Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, commented, “We are very excited to begin trading in the United States on OTC Markets under the ticker symbol “SSII”, the initials of the company that I founded over 10 years ago. SS Innovations has a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population, and we are now in a stronger position to make that happen with this foothold in the American capital markets. With our flagship “SSI Mantra” Surgical Robotic System, we have now trained over 50 robotic surgeons, completed over 180 surgeries across multiple specialties on six system installations, and have a rapidly growing pipeline of system orders, initially in India. Other milestones we expect to reach this year include, the development of Mixed Reality based Robotic Surgery Applications for teaching, training, patient education and portable telesurgery. We are also developing a comprehensive robotic surgery ecosystem to centralize patients, surgeons, proctors, clinical engineers, field service technicians, radiology centers, and other key beneficiaries to provide a seamless adoption of robotic surgery around the world for basic surgical healthcare. The systems have obtained all necessary medical device regulatory and commercialization approvals in India, which are also acceptable in many other countries with certain registration processes, and will plan on commencing the FDA and CE approval processes this year. With a strong foundation in place, we look forward to meeting the growing need around the world for our cutting edge and cost effective robotic surgical systems.” About SS Innovations International, Inc. SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system, and “SSI Mudra” is its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at www.ssinnovations.com Forward-Looking Statements This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. For Further Information Contact: PCG Advisory Stephanie Prince sprince@pcgadvisory.com (646) 863-6341 Contact Details Stephanie Prince sprince@pcgadvisory.com Company Website http://www.ssinnovations.com/

May 15, 2023 10:05 AM Eastern Daylight Time

Kadimastem Granted European Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, developing and manufacturing "off-the-shelf" allogeneic cell products using its platform technology to develop treatments for different neurodegenerative diseases and a potential cure for diabetes, has been granted a patent from the European Patent Office for its cell therapy technology IsletRx. IsletRx has been granted its fourth global patent approval for the company's innovative cell selection and enrichment technology, the company's treatment and potential cure for diabetes. The ability to select and enrich only the highest functioning and purest islet cells from the expanded and differentiated population of pluripotent stem cells enables the maximum therapeutic effect. Asaf Shiloni the CEO of Kadimastem stated: “The grant of this patent provides the crucial protection to our core Islet cells sorting technology, that is critical to achieve an effective cell therapy product for the treatment of diabetes. The European market holds great potential for our technology.” According to the International Diabetes Federation in 2021 “the Europe Region has the highest number of children and adolescents with type 1 diabetes – 295,000. Diabetes-related expenditure in the Europe Region totals USD 189 billion – 19.6% of its global expenditure. The Europe Region has the second highest average cost per person with diabetes (20-79y) – USD 3,086”[1]. In May 2021, the selection technology covered by this patent was described in a peer-reviewed journal article [2] in Frontiers in Endocrinology. About Kadimastem Kadimastem is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications. IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional, insulin and glucagon producing and releasing pancreatic islet cells, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). About IsletRx The IsletRx product is a clinical-grade collection of pancreatic islet cells. Preclinical studies have shown that the cells are able to detect the sugar levels in the body and to produce, and secrete, on demand, the required amounts of insulin and glucagon, just like a healthy pancreas and enables the insulin dependent patient to avoid an abnormal drop in sugar level (hypoglycemia). In addition, the method of production and selection of the cells enables their implantation in various types of smaller size devices, suitable for maximum comfort for people living with diabetes. [1] chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.mepinterestgroupdiabetes.eu/wp-content/uploads/2021/11/IDF-Atlas-Factsheet-2021_EUR.pdf [2] https://www.frontiersin.org/articles/10.3389/fendo.2021.635405/full At Kadimastem we envision being a global leader in cell therapy.Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Contact Details Kadimastem Sarah Bazak +972 73-797-1601 s.bazak@kadimastem.com Company Website https://www.kadimastem.com/

May 15, 2023 07:00 AM Eastern Daylight Time

News Release

Aclarion providing less invasive solution to treat lo back pain through augmented intelligence

Aclarion

Aclarion CEO Brent Ness joins Natalie Stoberman from the Proactive studio to share how the company utilizes augmented intelligence to treat chronic low back pain. Aclarion's innovative approach provides a less invasive way to pinpoint pain and offers promising results. The company's growth includes developing strong foundational technology, collaborating with key opinion leaders, and building compelling evidence through clinical trials and economic value analyses. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

May 11, 2023 12:41 PM Eastern Daylight Time

Video

mesoestetic® Selects ToolsGroup AI-Powered Planning To Support Burgeoning Business and Maximize Customer Satisfaction

ToolsGroup

ToolsGroup, a global leader in retail and supply chain planning and optimization software, is proud to announce it has been selected by mesoestetic, a global leader in the medical cosmetics and aesthetic medicine sector, to support the company’s massive business expansion while maintaining a premier customer experience. Founded in Spain in 1985, mesoestetic has grown from a distinguished pharmacy into a world leader in cosmeceutical and nutraceutical products, medical devices, and aesthetic medicine treatments. Its prolific product line – developed in close collaboration with hospitals, universities, and experience specialists – is available in 105 companies. It has a network of 94 official distributors, and 87% of its sales are international. “Thanks to the superior quality of our products, we are experiencing increasing customer demand, propelling us into the international market and spurring tremendous growth,” said Daniel Lancho Navarro, Operations Director at mesoestetic. “We needed a supply chain planning solution with unmatched forecasting to lay the foundation for customer-centric inventory and replenishment planning. Moreover, we built our business on collaborating with the leading minds in our sector. We wanted to carry this same spirit of collaboration and focus on continuous improvement into our supply chain revitalization. With its innovative AI and powerful automated solutions, ToolsGroup was the obvious choice for a supply chain collaborator who could refine our internal processes, support our continued business expansion, and maximize consumer satisfaction worldwide.” Focused on driving business performance and exceeding customer expectations, mesoestetic selected ToolsGroup Service Optimizer 99+ (SO99+), which includes Demand Planning & Forecasting, Inventory Optimization, and Replenishment. Armed with a unique, machine-learning-enhanced forecasting engine, SO99+ predicts and adapts to changes in demand for pinpoint forecast accuracy. It aligns inventory and replenishment plans with operations, improving and accelerating decision making so companies can hit business goals while increasing market share and boosting customer loyalty and satisfaction. “Amid increasing supply chain complexity, organizations are recognizing the tremendous growth potential inherent in the new economic landscape,” remarked ToolsGroup CEO, Inna Kuznetsova. “As AI and automation transition from novel to necessary, we see growth-oriented companies embracing collaborative processes and the latest technological innovations to drive profitable, customer-centric practices. That’s why we’re delighted to partner with mesoestetic on this supply chain transformation journey towards sustained business growth, higher profitability, and continued customer service excellence.” How can ToolsGroup enhance your supply chain management processes? Find out straight from our customers here. About mesoestetic At mesoestetic we are committed to bringing confidence, clarity, and scientific rigor to the world of beauty. From our beginning, 35 years ago, we have been committed to creating products of the highest quality and effectiveness backed by the results of numerous studies. We design home, aesthetic cabin and aesthetic medicine treatments to offer anti-aging, anti-acne, body reshaping, sun protection, and depigmenting solutions, where we are world leaders. We are a pharmaceutical laboratory that we design and produce at our headquarters in Viladecans (Barcelona). This differential factor is essential to guarantee the efficacy, quality and safety of all the treatments we develop, allowing us to control and take care of each step of the value chain. Thanks to all this, doctors, aesthetic professionals, consumers, and skincare experts trust us in more than 90 countries. About ToolsGroup ToolsGroup’s innovative AI-powered solutions enable retailers, distributors, and manufacturers to navigate through supply chain uncertainty. Our retail and supply chain planning suites empower a new level of intelligent decision making and unlock powerful business improvements in forecast accuracy, service levels, and inventory - delighting customers and achieving financial and ESG KPIs. Stay in touch with ToolsGroup on LinkedIn, Twitter, YouTube, or visit www.toolsgroup.com. Contact Details Meir Kahtan +1 917-864-0800 mkahtan@rcn.com Company Website https://www.toolsgroup.com

May 11, 2023 10:30 AM Eastern Daylight Time

Image

Rodedawg Intl. Ind., Inc. (OTC: RWGI) Expands into Healthcare with Acquisition of Elixicure™ Pain Relief

Rodedawg International Industries, Inc.

Rodedawg International Industries, Inc. (OTC: RWGI) Inc. proudly announces its expansion into the healthcare industry with the purchase of Elixicure™ Pain Relief. Chris Swartz, CEO of Rodedawg states, “We are very proud to announce to our shareholders that Rodedawg has acquired Elixicure™ and all its assets. Our shareholders are benefitting from the roadmap of 6 years of healthcare marketing experience and the evolution of the Elixicure™ brand. The Elixicure™ team raised over 3 and ½ million dollars and we are acquiring not only physical production equipment but we are gaining years of research, finalized formulas, packaging, branding, brand awareness and established revenue producing sales channels. The acquisition includes manufacturing equipment, transportation and warehouse equipment, sales personnel and sales channels with growing revenue streams. In its first few years of operation the company expanded exponentially and generated close to 1 million in revenues within 3 years of its start. The product set is already embedded in regional sports culture and has been a great success in chiropractic and healthcare centers. Rodedawg personnel will be adding to the management team and we fully expect to see Elixicure™ generate over 3 million in its first year as a Rodedawg company. This acquisition gives Rodedawg an the entrance into the multi-billion dollar pain relief market.” Chris Swartz, CEO, adds, “According to Allied Market Research, the global topical pain relief market size was valued at $8.8 billion in 2019, and is projected to reach $12.2 billion by 2027 at a CAGR of 5.2% from 2020 to 2027. This is a massive market and this acquisition positions the company to expand into products and services generating revenue streams back to the Rodedawg enterprise. Until the SAFE Banking ACT and national legalization of cannabis, this acquisition allows Rodedawg to develop channels of distributions with marketing and sales of products in mainstream national markets. Additionally, we will also be informing our shareholders of our expanded sales and marketing plan for Elixicure™ and a wide range of health care products with multi-faceted distribution sales channels.” Mr. Swartz concludes, “In the next few weeks, management will further inform shareholders on the timeframe and progress of accomplishing success milestones to further expand shareholder value. Behind the scenes, we are lining up additional acquisitions, cancellation of shares, and completion of our audit, as our plan from the beginning has been positioning the Company for significant growth leading to uplisting.” About Rodedawg International Industries, Inc. Rodedawg International Industries, Inc. (OTC: RWGI) is focused on providing management services, acquisitions, and restructuring resources throughout the regulated California cannabis market. We are a trusted partner and asset to licensed cultivation, distributors, manufacturers, and retail dispensaries Please note, the company's Twitter address is https://twitter.com/RWGImerger for regular updates. About Elixicure™ Elixicure™ Pain Relief creates, manufacturers and distributes high quality, organic pain relief without chemical additives. Founded in 2017 by two brothers who made it their mission to help their mother and the world by creating the best natural pain relief. The company website is https://elixicure.com/ Social Channels include: Facebook: https://www.facebook.com/Elixicure/ Instagram: https://www.instagram.com/elixicure/?hl=en https://www.youtube.com/channel/UC0FbyKmTYOxs6UTU_04F-mQ Purchase Online with Walmart at https://www.walmart.com/ip/Elixicure-All-Natural-Pain-Relief-Cream-Roll-on-Lavender-Scent Purchase Online with Amazon at https://www.amazon.com/Elixicure-Pain-Relief About Budding Horizon, LLC Budding Horizon, LLC is a California Limited Liability Company with offices in Orange County, California. The company is focused to providing management services for the licensed cannabis portfolio of assets. The company website is https://buddinghorizon.com/ Contact Information: Rodedawg International Industries, Inc. 1-800-793-0355 ir@buddinghorizon.com Safe Harbor Statement: In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company's future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company's business units or the market price of its common stock. Additional factors that would cause actual results to differ materially from those contemplated within this press release can also be found on the Company's website. The Company disclaims any responsibility to update any forward-looking statements. SOURCE: Rodedawg International Industries, Inc. Contact Details Rodedawg International Industries, Inc ir@buddinghorizon.com

May 11, 2023 09:30 AM Eastern Daylight Time

Emergent Health Subsidiary Evolutionary Biologics Executes Product Manufacturing Agreement with Major Player in the Regenerative Medicine Space

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that its subsidiary Evolutionary Biologics, Inc. (“EvoBio”), a developer, manufacturer and distributor of private label regenerative medicine products and branded state-of-the-art biologic products, created in a pharmaceutical grade laboratory and manufacturing facility has executed a Product Manufacturing Agreement with a distributor of medical devices that desires to market a MSC Exosome product from EvoBio as a private label on an exclusive basis. The Company believes the new relationship will generate at least $2 million in new revenue. Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated, “Our expansion of Evolutionary Biologics has continued beyond our original strategy. As I mentioned earlier this year, we have created a relationship with a state-of-the-art laboratory which has enabled us to not only manufacture the highest quality products for ourselves, but to manufacture world class products for strategic partners that can be marketed as “private label.” This new initiative comes as we continue to prepare the company for major growth and expansion.” On Tuesday of this week, Emergent announced the engagement of BF Borgers CPA PC, a full-service audit, tax, accounting, and advisory firm, as its Public Company Accounting Oversight Board (“PCAOB”) qualified auditor to audit the Company’s PharmaZu subsidiary’s financial statement for the two-year period ending December 31, 2022 according to Generally Accepted Accounting Principles (“GAAP”). GAAP is the accounting standard adopted by the Securities and Exchange Commission (“SEC”) and is the default accounting standard used by companies based in the United States. For further information, please see Press Release dated May 9 th, 2023. On Thursday of last week, Emergent announced the engagement of Boustead Securities LLC. to act as exclusive financial advisor with respect to a planned corporate financing transaction including the private placement of securities (“pre-IPO Financing”) and a planned $10 million initial public offering of Emergent;s subsidiary, PharmaZu and its common stock (“IPO”) that will apply for listing on NASDAQ with NO DILUTION to the Emergent Shareholders. PharmaZu is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness, using Influencers and their content, including pet pharmacy, vet telehealth and pet wellness businesses. Upon the effectiveness of the IPO and listing on NASDAQ, PharmaZu plans to acquire a 48-state authorized compounding pharmacy located in West Palm Beach, FL, doing approximately $10M a year in revenue, which will serve as the backbone and fulfilment center for PharmaZu, creating a national platform throughout the United States. The raise of capital will be used for expanding PharmaZu’s business, product offerings, as well as for acquisitions. Subsequently, Emergent plans to distribute the shares of PharmaZu as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. For further information, please see Press Release dated May 4 th, 2023. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 11, 2023 09:00 AM Eastern Daylight Time

Image

1 ... 126 127 128 129 130 ... 308